Welcome to our dedicated page for INTENSITY THERAPEUTICS SEC filings (Ticker: INTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Intensity Therapeutics, Inc. (Nasdaq: INTS) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing investors with direct access to official documents and AI-assisted analysis. As a late-stage clinical biotechnology company focused on intratumoral cancer therapies, Intensity’s filings offer detailed insight into its clinical programs, financial position, capital structure, and listing status.
Key filings include periodic reports such as Form 10-K and Form 10-Q, which describe the company’s business, risk factors, and financial statements, as referenced in its proxy materials. Current reports on Form 8-K document material events, including quarterly financial results, clinical trial updates like the INVINCIBLE-4 triple-negative breast cancer study, publication of the IT-01 Phase 1/2 data, amendments to bylaws affecting quorum requirements, Nasdaq compliance communications, and securities purchase agreements for registered direct offerings.
Investors can also review the company’s definitive proxy statements on Schedule 14A, which outline matters submitted to stockholders, such as proposals to approve a reverse stock split within a specified ratio range and potential adjournments of special meetings. These documents provide context on corporate governance decisions and the company’s approach to maintaining Nasdaq Capital Market listing requirements.
On Stock Titan, AI-powered tools summarize lengthy filings, highlight key sections, and help explain complex topics such as clinical trial disclosures, capital-raising transactions, and changes to governing documents. Users can quickly locate information on Intensity’s development of INT230-6, its interactions with Nasdaq regarding stockholders’ equity and minimum bid price rules, and other regulatory events. Form 4 and related insider transaction reports, when available, can be reviewed alongside these materials to understand trading activity by directors and officers. This centralized view of INTS filings supports more efficient, document-based research into the company’s oncology-focused business and regulatory history.
Intensity Therapeutics has filed an S-8 registration statement to register additional shares under its employee benefit plans. The registration covers:
- 529,300 additional shares of common stock under the 2021 Stock Incentive Plan (adding to 4,196,606 previously registered shares)
- 500,000 new shares under the 2024 Employee Stock Purchase Plan
The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. The filing incorporates by reference several documents including the company's 2024 Annual Report, Q1 2025 Quarterly Report, and recent Current Reports. The registration includes standard indemnification provisions for directors and officers under Delaware law, backed by D&O insurance coverage.